Core Viewpoint - ESGold Corp. has announced a brokered private placement offering to raise gross proceeds of up to C$5 million through the sale of units priced at C$0.75 each [1][2]. Group 1: Offering Details - The offering consists of up to 6,666,667 units, each unit comprising one common share and one warrant [1][2]. - Each warrant allows the holder to purchase one common share at a price of C$1.10 within 36 months following the closing date [2]. - The company has granted the agent an option to sell an additional 1,000,000 units for up to C$750,000 in gross proceeds [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing the Montauban Project in Québec and for general working capital and corporate purposes [4]. Group 3: Regulatory Compliance - The offering will comply with applicable regulatory requirements and will be available to purchasers in specific Canadian provinces, the United States, and offshore jurisdictions [5]. - The securities issued will be freely tradeable in Canada if sold to Canadian residents, without a hold period [5]. Group 4: Closing and Conditions - The offering is scheduled to close on September 18, 2025, subject to necessary regulatory approvals, including that of the Canadian Securities Exchange [7]. Group 5: Company Overview - ESGold Corp. is a pre-production resource company focused on clean mining and exploration, with its flagship Montauban property located 80 kilometers west of Quebec City [10].

Group 1 - Cartier Silver Corporation is proceeding with a non-brokered private placement for proceeds of up to $1.5 million [1][2] - The private placement will consist of up to 12,000,000 units at a price of $0.125 per unit, with each unit including one common share and one half of a common share purchase warrant [2] - Each warrant will allow the holder to purchase one common share at a price of $0.20 per share for a term of 36 months following the closing of the private placement [2] Group 2 - The net proceeds from the private placement will be used to finance exploration at the Chorrillos Project in Bolivia and for working capital purposes [3] - The private placement is subject to all required regulatory approvals, and all securities issued will be subject to a four-month hold period [3] Group 3 - Cartier Silver is focused on discovering and developing silver property assets, including the Chorrillos Project, and also holds significant iron ore resources and gold property [5]

Core Viewpoint - Prime Drink Group Corp. has terminated its rights offering and is moving forward with a non-brokered private placement to raise a maximum of $5,000,000 [1] Group 1: Private Placement Details - The private placement will offer units at a price of $5,000 per unit, each consisting of 62,500 common shares and 62,500 transferable share purchase warrants [2] - A maximum of 62,500,000 common shares will be issued at a deemed price of $0.08 per share, along with a maximum of 62,500,000 warrants [2] - Each warrant allows the holder to purchase a common share at $0.085 for two years from the issuance date [2] Group 2: Financial Aspects - The company will pay a cash finders' fee of 6% on the proceeds received from subscribers introduced by arm's-length finders [3] - The net proceeds from the unit offering will be used for business development and general working capital purposes [5] Group 3: Regulatory and Compliance - The units are offered through private placement exemptions from prospectus requirements under applicable securities laws, with resale restrictions including a hold period of four months and one day [4] - The offering is subject to final approval from the Canadian Securities Exchange and other regulatory approvals [4] Group 4: Company Overview - Prime Drink Group Corp. is based in Québec and aims to become a leading diversified holding company in the beverage, influencer media, and hospitality sectors [6]

Core Viewpoint - Genix Pharmaceuticals Corporation has successfully closed a non-brokered private placement, raising gross proceeds of $100,000 through the issuance of 2,000,000 units at a price of $0.10 per unit [1][2]. Group 1: Private Placement Details - The private placement consists of 2,000,000 units, each unit comprising one common share and one transferable common share purchase warrant [2]. - Each warrant allows the holder to acquire an additional share at a price of $0.10 for a period of two years, expiring on September 04, 2027 [2]. - The proceeds from the private placement will be utilized for general working capital and potential funding for new products [3]. Group 2: Insider Participation - The private placement was subscribed to by two insiders, the President and CEO, who collectively acquired all 2,000,000 units for $100,000 [5]. - This insider participation is classified as a "related party transaction" under Multilateral Instrument 61-101, allowing the company to be exempt from formal valuation and minority shareholder approval requirements [5]. Group 3: Regulatory and Legal Considerations - All securities issued will be subject to a hold period of four months and one day from the issuance date [4]. - The offering remains contingent upon receiving all necessary regulatory approvals, including from the TSX Venture Exchange [4]. - The offered securities will not be registered under the U.S. Securities Act and cannot be sold within the United States or to U.S. persons, except in certain exempt transactions [6]. Group 4: Company Overview - Genix Pharmaceuticals Corporation is a Canadian ophthalmic drug company focused on the research, development, manufacture, licensing, and sales of innovative ophthalmological products [7]. - The company aims to meet the increasing global demand for advanced eye-care solutions that enhance health and quality of life [7].

Group 1 - Eloro Resources Ltd. closed a "bought deal" private placement for gross proceeds of C$14,001,250, including full exercise of the over-allotment option [1] - The Offering involved the sale of 12,175,000 units at a price of C$1.15 per unit, with each unit consisting of one common share and one-half of a common share purchase warrant [1][2] - The net proceeds from the Offering will be used for exploration and development of the Iska Iska project in Bolivia, as well as for general corporate purposes and working capital [3] Group 2 - The Units were issued to Canadian purchasers under the listed issuer financing exemption, making the Unit Shares and Warrant Shares immediately tradeable under Canadian securities legislation [4] - Red Cloud Securities Inc. acted as the sole underwriter and received cash fees of C$980,087.50 and 852,250 non-transferable common share purchase warrants as compensation [5] - The securities offered have not been registered under the U.S. Securities Act and cannot be sold to U.S. persons without proper registration or exemptions [7] Group 3 - Eloro Resources is focused on exploration and mine development, with a portfolio that includes the Iska Iska Property in Bolivia, classified as a polymetallic epithermal-porphyry complex [8] - The Iska Iska project is road-accessible and royalty-free, and Eloro also holds an 82% interest in the La Victoria Gold/Silver Project in Peru [8]

Company Overview - NeuroSense Therapeutics Ltd. is a late-clinical stage biotechnology company focused on developing treatments for severe neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease, which represent significant unmet medical needs with limited therapeutic options available [5] Financing Details - NeuroSense has entered into a definitive agreement for a $500,000 private placement of ordinary shares, issuing 333,334 shares at a purchase price of $1.50 per share, which is a 40% premium to the closing price on September 3, 2025 [2][3] - The private placement is expected to close on September 8, 2025, subject to customary conditions, and the proceeds will be used for general corporate purposes and working capital [2] Management Commentary - The CEO of NeuroSense stated that this investment serves as a short-term bridge to advance the company's activities and prepare for the next stage of growth, emphasizing that this is the third financing with private investors at a premium to market [3]

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kodiak Copper Corp. (the “Company” or “Kodiak”) (TSX-V: KDK, OTCQB: KDKCF, Frankfurt: 5DD1) announces that it has entered into an agreement with Canaccord Genuity Corp. as lead underwriter (the “Underwriter”), in connection with a “bought deal” private placement for aggregate gross proceeds to the Company of approximately $7 million (th ...

Core Viewpoint - Kronos Worldwide, Inc. announced the sale of €75 million in additional 9.50% Senior Secured Notes due 2029 through an institutional private placement, which will be issued as additional notes to existing notes previously issued [1][3] Group 1: Notes Issuance - The additional notes will have the same terms as the existing notes, except for the issuance date and price [1] - The notes were oversubscribed and priced at a premium of 105%, with expected proceeds of approximately €78.8 million (around $91.9 million) before fees and expenses [3] - The closing of this offering is anticipated to occur on or about September 15, 2025, subject to customary closing conditions [3] Group 2: Use of Proceeds - The company intends to use the proceeds to pay amounts due under its 3.75% Senior Secured Notes maturing on September 15, 2025, or to repay any amounts drawn under its global revolving credit facility with Wells Fargo [3] - Any remaining net proceeds will be allocated for general corporate purposes [3] Group 3: Company Overview - Kronos Worldwide, Inc. is a leading global producer and marketer of titanium dioxide pigments, serving approximately 3,000 customers in 100 countries, primarily in Europe, North America, and the Asia Pacific region [6] - The company has developed considerable expertise in the manufacture, sale, shipment, and service of its products in both domestic and international markets [6]

As filed with the Securities and Exchange Commission on September 3, 2025. Registration No. 333-289984 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INDAPTUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Copies of all communications, including communications sent to agent for service, should be sent to: Gary Emmanuel, Esq. Greenberg Traurig LLP One Vanderbilt Avenue New Y ...

Core Viewpoint - IMPACT Silver Corp. has announced an increase in its bought deal private placement from approximately C$8 million to C$13 million due to strong investor demand [1] Group 1: Offering Details - The upsized offering will consist of 36,111,112 units priced at C$0.36 per unit, each unit comprising one common share and one warrant [1][2] - Each warrant allows the holder to purchase one common share at a price of C$0.45 within 24 months after the closing date [2] - An over-allotment option allows underwriters to purchase an additional 8,333,334 units for gross proceeds of up to approximately C$3 million [3] Group 2: Use of Proceeds - The net proceeds from the offering will be used for advancing underground development and infrastructure at the Guadalupe mine, increasing processing plant throughput, expanding mining operations at the Plomosas mine, and general working capital [7] Group 3: Regulatory and Closing Information - The offering is set to close on September 17, 2025, subject to necessary approvals, including from the TSX Venture Exchange [9] - The units will be offered to purchasers in all Canadian provinces except Québec and may also be sold in offshore jurisdictions [5]